Headlines

Syngenta acquires genetic repository from Novartis to boost biologic crop protection

Published by Global Banking & Finance Review

Posted on February 26, 2025

1 min read

· Last updated: January 25, 2026

Add as preferred source on Google
Ukrainian drone attacks on Russia's Tula region - Global Banking & Finance Review
Image depicting the aftermath of Ukrainian drone strikes in Tula and Nizhny Novgorod regions, highlighting the ongoing conflict and its impact on civilians. Relevant to recent drone attacks targeting industrial sites in Russia.
Global Banking & Finance Awards 2026 — Call for Entries

FRANKFURT (Reuters) - Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and genetic strains from drugmaker Novartis to further boost

Syngenta Acquires Novartis Genetic Repository for Crop Protection

FRANKFURT (Reuters) - Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and genetic strains from drugmaker Novartis to further boost development of biologic crop protection.

In its statement, China-controlled Syngenta said that Novartis will retain exclusive rights to the repository for pharmaceutical use, without disclosing financial terms.

Under the deal, Syngenta will lease a fermentation pilot plant and science laboratories in Basel as well as hire a team of biomolecular chemistry researchers at Novartis.

Syngenta has been investing to develop organisms, natural molecules, plant extracts, and other bio-based materials to complement its chemical crop protection products.

(Reporting by Ludwig Burger, Editing by Miranda Murray)

Key Takeaways

  • Syngenta acquires genetic repository from Novartis.
  • Deal focuses on biologic crop protection development.
  • Novartis retains pharmaceutical rights to the repository.
  • Syngenta leases facilities and hires researchers in Basel.
  • Investment in bio-based materials complements chemical products.

Frequently Asked Questions

What is the main topic?
The main topic is Syngenta's acquisition of a genetic repository from Novartis to enhance biologic crop protection.
What does the acquisition include?
The acquisition includes a repository of natural compounds and genetic strains, as well as leasing a fermentation pilot plant and science laboratories.
Who retains rights for pharmaceutical use?
Novartis retains exclusive rights to the repository for pharmaceutical use.

Related Articles

More from Headlines

Explore more articles in the Headlines category